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Background. Available blood assays for venous thromboembolism (VTE) suffer from diminished specificity. Compared with
single marker tests, such as D-dimer, a multi-marker strategy may improve diagnostic ability. We used direct mass
spectrometry (MS) analysis of serum from patients with VTE to determine whether protein expression profiles would predict
diagnosis. Methods and Results. We developed a direct MS and computational approach to the proteomic analysis of serum.
Using this new method, we analyzed serum from inpatients undergoing radiographic evaluation for VTE. In a balanced cohort
of 76 patients, a neural network-based prediction model was built using a training subset of the cohort to first identify
proteomic patterns of VTE. The proteomic patterns were then validated in a separate group of patients within the cohort. The
model yielded a sensitivity of 68% and specificity of 89%, which exceeded the specificity of D-dimer assay tested by latex
agglutination, ELISA, and immunoturbimetric methods (sensitivity/specificity of 63.2%/60.5%, 97.4%/21.1%, 97.4%/15.8%,
respectively). We validated differences in protein expression between patients with and without VTE using more traditional
gel-based analysis of the same serum samples. Conclusion. Protein expression analysis of serum using direct MS
demonstrates potential diagnostic utility for VTE. This pilot study is the first such direct MS study to be applied to
a cardiovascular disease. Differences in protein expression were identified and subsequently validated in a separate group of
patients. The findings in this initial cohort can be evaluated in other independent cohorts, including patients with
inflammatory conditions and chronic (but not acute) VTE, for the diagnosis of VTE.
Citation: Ganesh SK, Sharma Y, Dayhoff J, Fales HM, Van Eyk J, et al (2007) Detection of Venous Thromboembolism by Proteomic Serum
Biomarkers. PLoS ONE 2(6): e544. doi:10.1371/journal.pone.0000544
INTRODUCTION
Venous thromboembolism (VTE) occurs for the first time in ,100
per 100,000 persons each year in the United States. Approxi-
mately one third of patients with symptomatic VTE manifest
pulmonary embolism (PE) and two thirds present with deep vein
thrombosis (DVT)[1]. Death occurs within the first month in
approximately 12% of PE cases and 6% of DVT cases[1]. Current
noninvasive testing for VTE includes blood assays of D-dimer. D-
Dimer is a fibrin-specific degradation product that signifies
endogenous fibrinolysis of cross-linked fibrin. Several studies have
demonstrated good negative predictive value of D-dimer assays
but poor specificity as a marker of VTE[2,3]. A more accurate
biomarker would be of clinical value since management decisions
must be made promptly and accurately[4–6].
Multivariate strategies to disease diagnosis have been proposed
for risk assessment and clinical decision-making, in diseases such as
acute coronary syndromes[7,8]. The use of multiple markers may
provide a more accurate assessment of underlying conditions,
compared to single protein markers, especially in the case of
hemostasis[9]. We therefore hypothesized that a proteomic bio-
marker panel consisting of multiple serum proteins assessed
simultaneously would enhance the diagnostic accuracy for VTE
compared to D-dimer.
Mass spectrometry (MS) is a powerful analytic tool, capable of
analyzing complex protein mixtures. Since matrix-assisted laser
desorption/ionization time-of-flight (MALDI-TOF) MS can detect
a wide range of full length proteins, we hypothesized that
a MALDI-TOF MS approach could assay multiple protein
markers for the diagnosis of VTE. Protein expression patterns
apparent in mass spectra may be useful in a clinical setting if they
carry sufficient power as a biomarker in themselves, regardless of
whether protein identities are known[10,11]. In this approach,
multiple proteins can be assayed and used in a combinatorial
fashion to assess underlying diseases states. Validation of specific
protein expression patterns, defined as changes in either protein
concentration or post-translational modifications of proteins, can
then be carried out in subsequent experiments. However, the
appropriate application of MS for this purpose requires a detailed
understanding of the sources of variance in mass spectrometric
data and use of advanced computational methods[12]. We
systematically characterize sources of variation in the application
of direct MS to the analysis of whole serum and address
computational issues using a stringent approach to the analytic
methods developed for this study, guided by a series of simulation
experiments (Billings, E, unpublished data, 2006).
To test our hypothesis that protein expression patterns measured
across the serum proteome would have potential diagnostic utility in
VTE, we developed and applied a protein marker assessment that
uses MALDI-TOF MS and new computational approaches in
a cohort of hospitalized patients undergoing radiographic evaluation
for VTE. Diagnostic accuracy of D-dimer assays has been shown to
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PLoS ONE | www.plosone.org 1 June 2007 | Issue 6 | e544be especially problematic in this population[13]. Comparing the MS
results to other currently available VTE biomarkers in the same
cohort of patients demonstrates enhanced diagnostic precision of
serum protein markers identified by direct MS. Further, to address
whether direct MS methods detect changes in protein expression, as
opposed to noise or other chemical signatures, we validated
differential protein expression among patients with VTE by
performing 2-dimensional gel electrophoresis (2DGE) in a subset
of the cohort, demonstrating that differences in serum protein
expression are present in patients with VTE.
MATERIALS AND METHODS
Study Subjects
We studied 116 inpatients at Johns Hopkins Hospital undergoing
radiographic evaluation for VTE. Serum samples were obtained
from unselected inpatients at the time of radiographic testing
under a protocol which evaluated the diagnostic value of clinically
approved blood assays to detect VTE[13]. The protocol was
approved by the hospital institutional review board, and informed
consent was obtained from all participants. Serum samples,
baseline clinical information and results of diagnostic tests were
gathered (see Methods S1). Clinical characteristics were also
noted, including whether the patient had a history of surgery or
trauma within the week prior to enrollment, history of prior VTE,
or current diagnosis of cancer. Comparisons between the two
groups were performed using chi-squared binomial testing.
Clinical Methods
D-Dimer measurement D-Dimer assays were performed by
a technician blinded to patient information. Citrated plasma was
used for D-dimer ELISA (Dimertest Gold EIA; American
Diagnostics, Newport Beach, California), immunoturbidimetric
D-dimer assay (BCS; Dade Behring, Marburg, Germany), and
D-Di plasma agglutination assay (Diagnostica Stago, Asnieres,
France). A cutoff of 90 ng/mL was used as the upper limit of
normal for the D-dimer ELISA, based on prior studies
demonstrating a sensitivity for thrombosis .95%[13]. For the
immunoturbidimetric assay 1.0 mg/L was used as a cutoff. The
agglutination assay was interpreted as positive if agglutination
occurred in an undiluted specimen.
Radiologic Interpretation of VTE Radiologic studies were
performed per clinical standard of care at the hospital. Ultrasound
examinations included compression assessment of the deep veins.
Prospective investigation of pulmonary embolism diagnosis
(PIOPED) criteria were used for lung scan interpretation[14].
Final interpretations were made by the attending radiologist, who
was blinded to D-dimer results. All additional radiologic imaging
was performed within seven days after the index study, and
autopsy results for patients who died within seven days of
enrollment were included. VTE was defined as the presence of
an acute thrombus by ultrasound, CT scan, angiography, or
autopsy. Proximal lower-extremity deep vein thromboses were
included in this study when identified at the popliteal level or
higher. High probability lung scans were considered positive.
Proteomic Methods
A brief description of the proteomic methods is provided here,
with full details in Methods S1.
Direct MALDI-TOF mass spectrometry Serum samples
from patients with and without VTE were analyzed alternatively
after random selection of run order of each group. Serum samples
were thawed to 4 degrees Celsius, diluted 1:75 in deionized
HPLC-grade water and acidified with 0.1% trifluoroacetic acid.
Lactalbumin, which has a molecular weight of 14.2 kDa, was
added as an internal standard, or spike protein. The mixture of
serum and lactalbumin was co-crystallized in a 1:1 mixture with
3,4-dihydroxycinnamic acid matrix prepared in 50% water, 50%
methanol and 0.1% (v/v/v) TFA. Per serum sample, five MALDI-
TOF targets were prepared on a gold-coated plate. A total of 4
microliters of serum were used for preparation of the sample and
3.3 nanoliters were ultimately applied to each MALDI target spot.
The final concentration of the internal standard protein was 140.8
pM. Per sample, 14 protein expression profiles were obtained for
further computational analysis, using a Voyager-DE STR
Biospectrometry Workstation MALDI-TOF mass spectrometer
(Applied Biosystems, Foster City, California).
Computational Analysis A computational pipeline was
constructed to perform successive computational steps, including
data pre-conditioning, selection of training and test sets, data
reduction, analysis for protein expression differences, selection of
best models, and validation (Figure 1). Further methodologic
description can be found in Methods S1 (Figure S1).
(1) Data Pre-conditioning Each mass spectrum was
normalized to its total ion current. The 14 spectra from each
serum sample were then averaged, using a Tukey’s biweight
schema, yielding one normalized, averaged spectrum per patient
(Figure S2). Each final spectrum consisted of over 55,000
measurements of the mass-to-charge (m/z) ratios of the ions,
most of which are singly charged. Cluster analysis of the averaged,
normalized spectra identified 16 spectra with significantly elevated
baseline above the average baseline for the entire dataset (data not
shown). Since this baseline offset was not correctable using the
normalization schema applied, these spectra were excluded from
further analysis in the proof of principle experiments presented,
yielding 100 patients available for analysis.
(2) Partitioning of the Cohort The study cohort of 100
patients contained 38 patients with VTE. To balance the analyses,
38 patients without VTE were randomly selected for analysis,
excluding those spectra with baseline offset. The final study cohort
consisted of 76 patients and was randomly divided into three
groups: (1) a training set, to formulate the parameters for
automated classification, (2) a first test set (test set 1), to select
classification parameters that generalize best on new data, and (3)
a second test set (test set 2) that was completely withheld for
validation testing of the final system. The training set consisted of
38 patients, test set 1 consisted of 20 patients and test set 2
consisted of the remaining 18 patients. Each group contained
equal proportions of patients with and without VTE.
(3) Mass spectral data reduction To select the spectral
signals representative of relevant protein expression differences, an
ANOVA was applied across the mass spectra in the training set.
Figure 1. Computational pipeline used for analysis of direct MS data.
Successive computational steps were performed using a pipeline to
normalize, average and transform mass spectral data, perform ANN
analysis and establish performance metrics.
doi:10.1371/journal.pone.0000544.g001
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significant bins were selected for further model development.
(4) Analysis of protein expression differences The 500
selected spectral signals were log transformed (base 10), and
artificial neural network (ANN) analysis was performed. An ANN
was trained on the training set to develop model discrimination
parameters. The ANN was designed with a feed forward
architecture with a scaled conjugate gradient using MATLAB
(The MathWorks, Inc, 2002 v.6.5.018091a Release 13). The
trained network contained internal parameters called interconnec-
tion weights that served as model parameters that discriminate
between the patient groups within the training set.
The ability of the ANN to generalize on new data was then
optimized.2000ANNsweretrained,eachwithdifferentrandomized
values for the initial weights. This repetition allowed for greater
sampling of the possible sets of model parameters. Each network was
tested on test set 1, using the clinically relevant receiver-operator
characteristic (ROC) curve, plotting (sensitivity vs. 1-specificity) to
assess performance[15]. Area under the curve (AUC) and percent
correct were the primary endpoints for analysis. The network with
the best performancewasselectedforfurthervalidationtestingintest
set 2. The AUC based on performance in test set 2 was computed,
and sensitivity and specificity were determined.
Gel Electrophoresis Analysis of Serum Gel analyses were
performed on four patients with VTE and four age and gender
matched controls. Whole serum and serum conditioned for gel
electrophoresis were analyzed. Conditioned serum was prepared
according to methods recently developed to provide optimal results
for gel analysis of serum[16]. Briefly, serum was delipidated and
depleted of albumin and IgG (HiTrap protein G HP, Amersham,
Piscataway, NJ). Serum proteins were precipitated, resuspended in
SDS solubilization buffer (1% SDS, 10 mM HEPES, pH7.4) and
quantitated.
1-Dimensional Gel Electrophoresis 1DGE was performed
using precast 4–12% NuPAGE gels (Invitrogen, Carlsbad, CA).
Serum proteins (2 ml of whole serum or 17 mg of depleted serum)
were mixed with lithium dodecyl sulfate sample buffer and heated
at 70u C for 10 minutes prior to loading. After electrophoretic
separation, proteins were visualized with Coomassie staining
(CBB-R250, BioRad Laboratories, Hercules, CA).
2-Dimensional Gel Electrophoresis 2DGE and silver
staining of the resulting gels were performed using methods
previously published[16] (see Methods S1). 200 mg of protein from
the preparation of conditioned serum was analyzed on each gel.
Gels were run and stained in pairs, containing one patient with VTE
and a paired control without VTE.
Computer-assisted gel image analysis A digital image of
each gel was acquired with a PowerLookII scanner at 600 dpi
(UMAX Technologies, Inc., Dallas, TX). Protein spots or bands
were aligned using Progenesis
TM Workstation software (C2005,
Nonlinear Dynamic, Newcastle, UK).
MS protein identification After 2DGE, spots were manually
excised and digested for MS/MS analysis, using methods described
in the Methods S1 section. Data analysis was performed using an
NIH-supported version of Mascot (Matrix Science, London, UK).
Evaluation of Reproducibility of Methods: Regarding the
MS analysis of serum and computational analysis, MS is a very
precise tool for evaluating the mass of proteins, represented as the
m/z ratio, on the x-axis of the mass spectrum. The intensity of
peaks obtained in mass spectral data (which is displayed on the y-
axis of the mass spectrum), however, are prone to variability.
Therefore, we used several replicates per patient analyzed. To
document the effectiveness of replication in reducing variability,
we analyzed a single serum sample from one patient 100 times,
using the final method, and calculated a coefficient of variation
(CV) across the replicates (CV=0.10). A CV of 0.15 or less
generally indicates highly reproducible data, and thus, we were
satisfied that replication is an effective strategy to reduce variability
for our analysis of mass spectra derived from serum. In our study,
we analyzed 14 replicates per patient. Across the entire spectrum
of m/z ratios, the CV with this number of replicates ranged from
0 to 1, with typical values near 0.8. The bins selected for use in the
classifier, as described in the section ‘‘Mass spectral data reduction,’’
showed a CV in the range of 0.3 or less. These CVs are in an
acceptable range to demonstrate reproducibility of the data used by
the classifier to distinguish VTE and non-VTE groups.
For the one- and two-dimensional gel electrophoresis analyses, we
applied methods that have been published[16] and demonstrate
a high degree of reproducibility of the final gel results. MS-based
identification of proteins separated by gel electrophoresis was
validated as well, with highly reproducible results from multiple
gels[16].
RESULTS
Clinical Characteristics
Baseline clinical characteristics were compared between the
patient groups. Among the 100 patients eligible for the study and
76 patients ultimately analyzed, there were no differences between
patients with and without VTE, with respect to age, gender, history
of recent surgery or trauma, or presence of advanced malignancy
(Table 1). Patients with VTE did more often have a history of prior
VTE (p=0.0003). CRP and fibrinogen levels were not significantly
different between the two groups (Table 1).
Diagnostic radiographic imaging modalities used to assess
whether VTE was present included ultrasound imaging of the
extremities, V/Q scans, CT scans, venography and pulmonary
angiography. The overall proportion of imaging modalities used was
not significantly different between the patient groups, comparing the
use of each individual modality between the groups. Among patients
diagnosed with VTE, 13 patients (34.2%) had DVT only, 19 (50%)
had PE only and 6 (15.8%) were diagnosed with both DVT and PE.
Direct mass spectrometry analysis of serum
Individual serum analysis yielded a reproducible spectrum in which
the spike protein was visualized in 100% of samples analyzed
(Figure 2a, 2b). Expression of the internal spiked-in control protein
showed equivalent intensity across all samples, with a CV of 0.034.
No difference in expression was noted of the spiked-in protein in the
ANOVA between patients with and without VTE (p=0.53).
Correlation (r
2) of all m/z ratios for the 14 spectra acquired per
patient was 0.9601 (standard deviation 0.0170). The average
correlation between patients was 0.9593 (standard deviation
0.044). These measures of inter- and intra-individual variability
are consistent with other, similar proteomic methodologies[17,18].
To explore overall changes in protein expression, an average
spectrum was computed from all patients with VTE and another
from patients without VTE. The ANOVA applied across all mass
spectral data, comparing VTE and NoVTE spectra, yielded a p-
value for each point on the x-axis of the mass spectra. Rank
ordering the p-values, the 500 smallest p-values all were p,0.033,
without multiple testing corrections (Figure 2c).
ANN-based classification of protein expression
profiles
TheANN-basedclasspredictionmodeldevelopedonthetrainingset
and optimized in test set 1 ultimately classified 78% of patients
Proteomics of Thromboembolism
PLoS ONE | www.plosone.org 3 June 2007 | Issue 6 | e544correctly in test set 2. In this, blinded independent validation group,
77% of patients with VTE were correctly classified and 89% of
patients without VTE were correctly classified. The specificity of the
model exceeded the specificity of any D-dimer method in tested in
both the validation group as well as the entire cohort, tested by latex
agglutination, ELISA, and immunoturbimetric methods which
showed sensitivity/specificity of 63.2%/60.5%, 97.4%/21.1%,
97.4%/15.8%, respectively (Table 2). In the validation group, an
AUC of 0.85 was determined by plotting the ROC of sensitivity vs.
(1-specificity) (Figure 3). The AUC for blood D-dimer levels
assessed by ELISA and immunoturbimetric methods were 0.70 and
0.62 respectively. Examining the ROC curves for the two D-dimer
tests with continuous values reported by the clinical laboratory on all
76 patients studied, the ANN-based prediction model performed
best. Using a resampling method to generate confidence intervals
and a parametric t-test to compare AUCs in test set 2, the improved
ANN performance is significant (p,0.001).
To examine possible confounding effects of inflammation,
introduced through prior VTE or concurrent cancer diagnosis,
misclassification rates were tabulated. Chi-squared statistics (df=3)
demonstrated no significant relationship between CRP and
classification errors (p=0.72 in all patients, n=78; p=0.27 in
test set 2, n=18).
Gel electrophoresis of serum proteins
1DGE and 2DGE were next undertaken on a subset of the cohort,
to determine whether serum protein expression differences that
were detected and used by the ANN-based classification method of
direct MS data could be validated by established proteomic
techniques used to characterize protein expression.
1DGE performed on whole serum showed very few protein
bands other than albumin and no discernable differences between
serum samples from patients with and without VTE (Figure 4a).
Table 1. Baseline characteristics of the patient cohort*.
..................................................................................................................................................
(a) 100 patients eligible for analysis
All (N=100) VTE (N=38) No VTE (N=62)
Age-years 55.92616.59 54.92618.94 56.53615.11 p=0.6398
Male-no. (%) 41 (41.0) 14 (36.84) 27 (43.55) p=0.5081
Post-operative-no. (%) 28 (28.0) 11 (28.95) 17 (27.42) p=0.8688
Cancer-no. (%) 33 (33.0) 16 (42.11) 17 (27.42) p=0.1295
Prior VTE-no. (%) 17 (17.0) 13 (34.21) 4 (6.45) p=0.0003
Hypertension-no. (%) 10 (10.0) 4 (10.53) 6 (9.68) p=0.8921
Diabetes-no. (%) 5 (5.0) 2 (5.26) 3 (4.84) p=0.9256
Renal dysfunction-no. (%) 3 (3.0) 0 (0) 3 (4.84) p=0.1719
Pulmonary disease-no. (%) 4 (4.0) 0 (0) 4 (6.45) p=0.1122
Coronary artery disease-no. (%) 3 (3.0) 1 (2.63) 2 (3.23) p=0.8674
Congestive heart failure-no. (%) 4 (4.0) 1 (2.63) 3 (4.84) p=0.5890
Hepatic dysfunction-no. (%) 3 (3.0) 0 (0) 3 (4.84) p=0.1719
HIV-no. (%) 1 (1.0) 0 (0) 1 (1.61) p=0.4365
Plasma CRP-mg/ml 5.9067.04 5.0665.05 6.4168.02 p=0.3566
(b) 76 patients selected for analysis
All (N=76) VTE (N=38) No VTE (N=38)
Age-years 55.57616.99 54.921618.94 56.21615.02 P=0.7432
Male-no. (%) 32 (42.11) 14 (36.84) 18 (47.37) P=0.3527
Post-operative-no. (%) 22 (28.95) 11 (28.95) 11 (28.95) p=1.0
Cancer-no. (%) 25 (32.89) 16 (42.11) 9 (23.68) p=0.0874
Prior VTE-no. (%) 15 (19.74) 13 (34.21) 2 (5.26) p=0.0015
Hypertension-no. (%) 8 (10.53) 4 (10.53) 4 (10.53) p=1.0
Diabetes-no. (%) 3 (3.95) 2 (5.26) 1 (2.63) p=0.5621
Renal dysfunction-no. (%) 2 (2.63) 0 (0) 2 (5.26) p=0.1600
Pulmonary disease-no. (%) 2 (2.63) 0 (0) 2 (5.26) p=0.1600
Coronary artery disease-no. (%) 2 (2.63) 1 (2.63) 1 (2.63) p=1.0
Congestive heart failure-no. (%) 3 (3.95) 2 (5.26) 1 (2.63) p=0.5621
Hepatic dysfunction-no. (%) 2 (2.63) 0 (0) 2 (5.26) p=0.1600
HIV-no. (%) 1 (1.32) 1 (2.63) 0 (0) p=0.3238
Plasma CRP-mg/ml 5.7067.37 5.0665.05 6.3369.16 p=0.4561
Fibrinogen-mg/ml 470.646212.71 460.876195.88 480.156230.09 p=0.6930
*Plus-minus values are means6SD
doi:10.1371/journal.pone.0000544.t001
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PLoS ONE | www.plosone.org 4 June 2007 | Issue 6 | e5441DGE of conditioned serum, that had been delipidated and
depleted of high abundance proteins, showed many distinct bands
of varying intensity. However, no clear patterns between the
patient groups were discerned with visual inspection or computer-
assisted analysis (Figure 4a). 2DGE demonstrated differences in
serum protein expression between patients with and without VTE
(Figure 4b). Several spots were excised from the gel and
successfully identified using MS/MS for sequence-based protein
identification (Supplemental Table S1). Proteins identified
include haptoglobin, platelet coagulation factor XI, complement 9,
plasma kallikrein B1 precursor, immunoglobulin alpha-1 heavy
chain constant region, proapolipoprotein and alpha-1B glycopro-
teins (Figure S3). Proteins known to be of relatively high
abundance in human serum were easily detected by visual
inspection of serial gels. Differential expression was noted of
proteins such as haptoglobin, alpha-1B glycoproteins, and others,
validating that protein expression differences are present in serum
of patients with and without VTE.
Figure 2. Direct MS of serum. Average spectra for patients with VTE (a) and without VTE (b) show differences in overall protein expression, with the
internal spike protein denoted by an asterisk. The 500 signals selected by the ANOVA analysis are denoted by red circles, representing locations on
the mass spectrum with differential protein expression between the two groups of patients (c).
doi:10.1371/journal.pone.0000544.g002
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Clinical biomarkers used to diagnose cardiovascular disease
typically consist of single protein markers. However, since multiple
proteins interact in processes such as thrombosis, it is reasonable to
hypothesize that a panel of multiple protein markers may more
accurately detect a disease. We hypothesized that an intravascular
thrombus would result in protein expression differences that could
be detected using direct MS. After establishing a reproducible and
relatively simple direct MS method to analyze serum, we
successfully applied advanced computational methods to develop
a discrimination model. Final validation of the model in an
independent, withheld subset of the data demonstrated enhanced
diagnostic performance compared to routinely available D-dimer
assays. Gel-based analyses validated that protein expression
differences between the patient groups are present among proteins
with relatively high abundance in serum.
We used a direct MS method to analyze serum in this study,
using MALDI-TOF MS. Other clinical proteomic approaches
using direct MS have typically employed a technology known as
Surface Enhanced Laser Desorption Ionization (SELDI) to enrich
for subsets of proteins on the MS sample target surface[10,19].
The advantage of this approach is that the protein mixture is
simplified, in that only those proteins with a specific biochemical
property adhere to the given SELDI surface, providing stronger
MS signals from the enriched set of captured proteins. However,
this process may alter relative protein abundance, potentially
diminishing the ability to detect meaningful differences in relative
protein expression of those proteins with sufficient abundance to
detect without such pre-enrichment steps. Additionally, technical
Figure 3. ROC characteristics for the direct MS method in the independent test set compared to standard D-dimer tests. The optimized model
shows comparable ROC curves in test set 1 (TST1) and test set 2 (TST2). D-Dimer by ELISA and immunoturbimetric assay results are plotted for all 76
patients in the cohort for comparison.
doi:10.1371/journal.pone.0000544.g003
Table 2. Performance of the direct MS method of assessing
protein markers of VTE compared to d-dimer.
......................................................................
Overall cohort: 100 patients
Sensitivity Specificity
Latex agglutination d-dimer 63.20% 58.10%
ELISA d-dimer 97.30% 19.40%
Immunoturbimetric d-dimer 97.30% 16.10%
Overall cohort: 76 patients
Sensitivity Specificity
Latex agglutination d-dimer 63.20% 60.50%
ELISA d-dimer 97.40% 21.10%
Immunoturbimetric d-dimer 97.40% 15.80%
Validation Group: 18 patients
Sensitivity Specificity
Latex agglutination d-dimer 55.60% 77.80%
ELISA d-dimer 100% 33.30%
Immunoturbimetric d-dimer 100% 22.20%
Direct MS method 67.70% 88.90%
Sensitivity and specificity of the direct MS method is compared to the results of
standard clinical d-dimer assays performed in the cohort.
doi:10.1371/journal.pone.0000544.t002
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PLoS ONE | www.plosone.org 6 June 2007 | Issue 6 | e544issues such as inter- and intra-chip variation can be an issue with
SELDI methodologies. Therefore, the relative utility of our
method and established SELDI approaches is unknown. We
chose to apply MALDI-TOF MS on serum processed minimally,
aiming to preserve relative protein expression levels as close to the
original serum sample as possible. Further, we go on to validate
protein expression differences using gel-based proteomic methods.
The approach to data analysis in this study deserves specific
consideration in light of potential pitfalls of direct MS method-
ologies. Given that mass spectra are prone to variability in
ionization efficiency, we applied a standardized method of
analyzing serum directly with MALDI-TOF MS, using averaging
of technical replicates and normalization to a measure of total
ionization efficiency by the laser. Technical replication and
normalization of data are well-validated approaches to deal with
variability in other genomic methodologies, such as microarray
transcript expression profiling[20]. Consistency of the internal
spike protein across samples demonstrates that variability of MS
data can be successfully managed using these methods.
Machine learning methods applied to direct MS data carry risks
of confounding, bias, and overfitting[21]. Confounding and bias
were avoided by using available serum samples without selection
for this study, from a single enrollment center in which all samples
were handled identically, to minimize the influence of pre-analytic
factors. Sample analysis was conducted in a blinded manner.
Overfitting is a problem commonly encountered in genomics
research, in which a large number of potential predictors are used
to discriminate between patient outcome groups[22]. This is
clearly a risk in the analysis of direct MS data[23–25]. To
minimize this risk, we applied an exceptionally stringent approach
that divides the study cohort into a training set and two test sets.
Despite the resulting diminished sample size in each group, we
demonstrate enhanced diagnostic performance of the direct MS
method using the well-validated receiver operator curve char-
acteristics. Thus, we are able to directly compare sensitivity and
specificity of the proteomic expression profiles to currently
available single marker tests for D-dimer.
Limitations of this study include the determination of VTE
outcome as that made in the routine clinical setting. The gold
standard for pulmonary embolus is pulmonary angiography, and
for deep venous thrombosis, it is venography[26–29]. An
observational approach was used in this study, given the
exploratory nature of the analyses performed here. Testing was
conducted with a small sample size, and further validation in
a larger study will be needed to verify these results. In addition,
MS patterns can be studied in two additional groups: patients with
a history of VTE but not an acute VTE (examining the proteomic
profile of chronic VTE in the absence of an acute event); and
patients with a chronic inflammatory condition, in the absence of
VTE. These two additional groups would address the MS pattern
chronic inflammation or chronic VTE and overlap with acute
VTE. These studies will be conducted in future work.
To address whether the detected MS signals used by the model
to categorize patients with and without VTE do in fact reflect
protein expression differences, we present focused data from 2DGE
corroborating differential protein expression identified between the
patient groups. This suggests that the direct MS method is capable
of detecting differences in protein expression in whole serum of
those proteins of sufficient abundance to be detected by 2DGE
performed on depleted serum. Further, our findings suggest that
direct MS, a relatively simply analytic method using very little
serum, may potentially be useful for guiding subsequent proteomic
analyses aimed to identify specific protein markers of disease.
Specific validation of protein markers identified in this study
requires further focused examination of these proteins.
We performed this pilot investigation in a population of
hospitalized patients. These patients had other potential con-
founders including recent trauma, surgery and cancer, which are
known to alter predisposition to thrombosis and may alter
coagulation protein expression patterns in the absence of an
intravascular thrombus. Additionally, prior VTE was found to be
more common among patients with acute VTE, consistent with
other studies but also possibly acting as an additional confounder.
Reliable blood based assays would be of value in this population,
where currently available markers of VTE suffer from low
specificity[30]. We chose this more diagnostically challenging
group of patients for the proof of principle experiment presented
here, to determine if this method could detect protein expression
differences against a biologically ‘‘noisy’’ background. Since the
direct MS method was able to detect meaningful changes in this
population, we hypothesize that the method will be robust to
patient-to-patient variation and other sources of variability that
would be commonly encountered in clinical application.
Given that the direct MS method described represents a non-
invasive test that can be performed rapidly, inexpensively and in
an automated fashion, requiring only 10 nanoliters of serum, this
technology holds promise for clinical application. As FDA-
Figure 4. Gel electrophoresis of serum from patients with and
without VTE. 1-DGE of whole serum and depleted, conditioned serum
was run on 4 VTE and 4 NonVTE patients (a). 2-DGE was performed on
serum from patients with VTE and without VTE, with arrows pointing to
a series of haptoglobin proteins with differential expression between
VTE and NonVTE patients, displayed in two representative gels (b).
doi:10.1371/journal.pone.0000544.g004
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expression patterns using SELDI-TOF MS for the diagnosis of
diseases such as cancer, direct MALDI-TOF of serum may be
a complementary approach deserving of consideration for
applications such as VTE[31]. Importantly, validation of novel
biomarkers requires rigorous testing in large cohorts to determine
the potential clinical utility[15]. In the case of VTE, testing
diagnostic utility in conjunction with clinical risk stratification and
radiographic modalities will be essential[32–34]. While currently
available diagnostic protocols using the D-dimer assay provides
a high negative predictive value, the proteomic markers we
identified appear to add specificity to currently available blood
assays. In the future, a combination of methods may provide
optimal sensitivity and specificity, including ultrasound compres-
sion, D-dimer testing and possibly a MS test to help clarify
situations in which the diagnosis of DVT and PE could not be
made by the first two tests. In addition, with further research, we
may be able to develop a potential model using all modalities,
combining new markers identified through proteomic methods
such as ours and future efforts to further refine these, in
combination with currently available clinical methods such as D-
dimer testing and compression ultrasound. Our analysis provides
the basis for proposing a potential model using proteomic
modalities in combination with currently available clinical methods,
such as D-dimer testing, compression ultrasonography and radio-
graphic testing for VTE. We envision that future practical
application will likely require further independent validation of our
findings and further proteomic analysis to identify the specific
markers underlying the mass spectral signals detected in our work.
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Figure S1 Computational pipeline used for analysis of direct MS
data. Successive computational steps were performed using
a pipeline to normalize, average and transform mass spectral
data, perform ANN analysis and establish performance metrics.
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TIF)
Figure S2 Averaging of mass spectra per patient. For 4 different
patients studied, the 14 raw mass spectra are shown, with the final
averaged spectrum below each set of raw mass spectra.
Found at: doi:10.1371/journal.pone.0000544.s004 (11.65 MB
TIF)
Figure S3 MS/MS data for haptoglobin. The raw chromato-
gram is shown (a, upper panel) along with the chromatogram for
the peptide YVMLPVADQDQCIR with observed mass of 854.41
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raw MS/MS data (c).
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